Detection of Impurities in Bulk Drug and Capsule of Fluconazole
Objectives: The purpose of this study was to identify the impurities and their amounts in the fluconazole bulk drug and capsule FLUNACTM (150 mg). Method: HPLC with diode array detector was used to carry out the study. The composition of mobile phase was acetonitrile: water (85:15 %) with flow rate of 0.7 mL/min and detected at 260 ± 1 nm. Results: Two impurities (one is known impurity A and other unknown impurity) were detected in the bulk drug and also in capsule FLUNAC (150mg). The total amount of impurities in fluconazole bulk drug and capsule were 0.368% and 0.392% respectively. Conclusion: The total amount of impurities was less than 1% which is acceptable.
2. Vensel TD. Fluconazole: a valuable fungistatic. Primary care update for ob/gyns. 2002; 9(5):181-3.
3. Stern JJ, Hartman BJ, Sharkey P, Rowland V, Squires KE, Murray HW, Graybill JR. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. The American journal of medicine. 1988; 85(4):477-80.
4. Fox R, Neal KR, Leen CL, Ellis ME, Mandal BK. Fluconazole resistant Candida in AIDS. Journal of Infection. 1991; 22(2):201-4.
5. Petitjean O, Jacolot A, Tod M. Pharmacologie des antifongiques azolés systémiques. Médecine et Maladies Infectieuses. 1995; 25:14-26.
6. Zervos M, Meunier F. Fluconazole (Diflucan®): a review. International journal of antimicrobial agents. 1993; 3(3):147-70.
7. Rogers TE, Galgiani JN. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrobial agents and chemotherapy. 1986; 30(3):418-22.
8. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrobial agents and chemotherapy. 1985; 28(5):648-53.
9. Anandkumar Y, Kapse-Mistry S, Kadu P. UV spectrophotometric method development and validation for estimation of fluconazole. World Journal of Pharmaceutical Research. 2015 Aug 17; 4(11):814-21.
10. Roy J. Pharmaceutical impurities-a mini-review. AAPs PharmSciTech. 2002; 3(2):1-8.
11. Misbahuddin M, Islam MS, Sarker UK. Detection of Impurities in a tablet of Atorvastatin. KYAMC Journal. 2011; 1(2):43-7.
12. Bari SB, Kadam BR, Jaiswal YS, Shirkhedkar AA. Impurity profile: significance in active pharmaceutical ingredient. Eurasian journal of analytical chemistry. 2007; 2(1):32-53.
13. Scriba GK. Selected fundamental aspects of chiral electromigration techniques and their application to pharmaceutical and biomedical analysis. Journal of pharmaceutical and biomedical analysis. 2002; 27(3-4):373-99.
14. International Conference on Harmonisation-ICH. Draft revised guidance on impurities in new drug products. Fed. Regist. Q3B (R). 2000; 65(139):44791.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).